Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: December 3, 2022

Details for Patent: 8,715,624

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,715,624 protect, and when does it expire?

Patent 8,715,624 protects TOPICORT and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 8,715,624
Title:Stable liquid desoximethasone compositions with reduced oxidized impurity
Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C.sub.2-C.sub.4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C.sub.2-C.sub.4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-androsta-1,4- -diene-3-one under an accelerated storage condition.
Inventor(s): Rao; Srinivasa (Valley Stream, NY), Dixit; Suresh (Ft. Worth, TX), Yacobi; Avraham (Englewood, NJ), Bailey; Arthur (Bethel, CT)
Assignee: Taro Pharmaceuticals North America, Inc. (Grand Cayman, KY)
Application Number:13/605,622
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,715,624
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery; Use; Process;

Drugs Protected by US Patent 8,715,624

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Taro Pharms TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 AT RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,715,624

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2609579 See Plans and Pricing
European Patent Office 1888026 See Plans and Pricing
Israel 187666 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006130510 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.